Stephen BeersProfessor of Immunology and Immunotherapy, University of Southampton Stephen Beers is Professor of Immunology and Immunotherapy at the Centre for Cancer Immunology, University of Southampton. He leads a research group studying antibody drugs and their mechanisms of action. The group’s research is currently focussed on two main areas: 1) the mechanisms of action of immunomodulatory mAb, and 2) how the tumour microenvironment affects antibody effector function and how this might be manipulated to enhance patient outcomes. Their work utilises a portfolio of complimentary models incorporating in vitro 3D modelling, appropriate in vivo model systems and primary clinical material. |
Sara ColombettiGlobal Head Oncology Discovery Pharmacology, pharma Research and Early Development (pRED), Roche Innovation Center Zürich I have received my Ph.D. in Molecular and Cellular biology at the San Raffaele Scientific Institute in Milan (Italy). After a post-doc in cancer immunotherapy at the Ludwig Institute for Cancer Research (Lausanne branch) and later at Cytos Biotechnology (Zurich), I have joined the Roche Innovation Center Zurich in 2009. There I have led first the preclinical in vivo models group, then the Immuno-pharmacodynamics and Bioanalytics group and have been appointed as global Head of the Oncology Discovery Pharmacology Department in 2018. |
Elena MeniettiScientist, Oncology Discovery Pharmacology, pharma Research and Early Development (pRED), Roche Innovation Center Zürich Elena Menietti received her Ph.D. in Cancer and Immunology at the University of Lausanne, Switzerland, in 2016. She then joined Roche Oncology Discovery Pharmacology for her post-doctoral studies in the Pre-clinical Imaging group, and was appointed scientist in the Pre-clinical Imaging and Histology group. She is in charge of developing new imaging tools to explore the tumor microenvironment in response to cancer immuno-therapy. |
Graham PockleyDirector and Professor, John van Geest Cancer Research Centre, Nottingham Trent University, CEO, multimmune GmbH Professor A. Graham Pockley, PhD is the CEO of multimmune GmbH (www.multimmune.com), Munich, Germany. multimmune’s unique and proprietary technology platform is based on the discovery (by Gabriele Multhoff and Claus Botzler) that a cell surface bound form of Hp70 is selectively and widely expressed on the plasma membranes of many tumour entities. multimmune is developing innovative theranostics on the basis of membrane Hsp70 expression by tumour cells, including an autologous NK cell-based therapy (ENKASTIMev) |
Ed SchuuringProfessor in Molecular Oncological Pathology, University Medical Center Groningen Prof Dr Ed Schuuring, PhD, senior clinical scientist in molecular pathology, University Medical Center Groningen, Groningen, The Netherlands |
